Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Jacksonville, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
706
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Jacksonville, FL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Jacksonville, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 673–684 of 706 matching trials with a site at Mayo Clinic, Jacksonville, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

NCT05394103
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer
Interventions
Q901, KEYTRUDA® (pembrolizumab)
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Active, not recruiting Not applicable Interventional

A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer

NCT05027477
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Radical Prostatectomy, TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Recruiting No phase listed Observational

A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study

NCT07045103
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Lung Biopsy
Interventions
Not listed
Lead sponsor
Invenio Imaging Inc.
Industry
Eligibility
22 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Diego, California • Jacksonville, Florida • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Recruiting Phase 2 Interventional

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615
Status at this site: Recruiting
View directory record Official record
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Recruiting Phase 1 Interventional

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT05785754
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
DCSZ11, Pembrolizumab, Doxorubicin, Tebentafusp
Drug
Lead sponsor
DynamiCure Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Not yet recruiting Phase 3 Interventional

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

NCT06973629
Site status not listed — check the official record
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Interventions
Debamestrocel - MSC-NTF (NurOwn), Placebo
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Not yet recruiting Not applicable Interventional

Combined Local Anesthetic Blockade and Neuromodulation vs Local Anesthetic Blockade Only for Analgesia After Below-knee Amputation: RCT

NCT06964347
Site status not listed — check the official record
View directory record Official record
Conditions
Amputation
Interventions
Ropivacaine 0.2% + nerve stimulator set, Ropivacaine 0.2%
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Stanford, California • Jacksonville, Florida • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
Status at this site: Recruiting
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NCT02912949
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Interventions
zenocutuzumab (MCLA-128)
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
26
States / cities
Phoenix, Arizona • Cerritos, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Recruiting Phase 1 Interventional

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

NCT04215809
Status at this site: Recruiting
View directory record Official record
Conditions
CLL/SLL
Interventions
Lisaftoclax
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Duarte, California • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 26, 2026, 4:01 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

NCT04164901
Site status not listed — check the official record
View directory record Official record
Conditions
Grade 2 Glioma, Residual Glioma, Recurrent Glioma
Interventions
Vorasidenib, Matching Placebo
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 26, 2026, 4:01 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Jacksonville, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.